Kellner Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Kellner Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-16,300	Closed	-$11K	–	43
2020 Q4	$11K	Hold	16,300	–	–	0.01%	29
2020 Q3	$37K	Hold	16,300	–	–	0.02%	28
2020 Q2	$58K	Hold	16,300	–	–	0.03%	23
2020 Q1	$62K	Sell	16,300 -18,000	-52%	-$59.3K	0.03%	32
2019 Q4	$103K	Buy	+34,300	New	+$89.2K	0.07%	31

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Kellner Capital's BMY.RT Position: Q1 2021 in Review

Kellner Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 16,300 shares — an estimated $11K sold.

Kellner Capital first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $103K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Kellner Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Kellner Capital sold 16,300 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $11K.
Kellner Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Kellner Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $103K in Q4 2019.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Kellner Capital's 13F filing for Q1 2021, filed 10 May 2021.